ALBIO.PA
Biosynex SA [ALBIO.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALBIO.PA Stock Summary
Top 10 Correlated ETFs
ALBIO.PA
Top 10 Correlated Stocks
ALBIO.PA
In the News
ALBIO.PA Financial details
Company Rating
Strong Buy
Market Cap
90.74M
Income
1M
Revenue
33.48M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
380
Optionable
No
Shortable
Yes
Earnings
19 Jan 2023
P/E
4.27
Forward P/E
18.06
PEG
-0.43
P/S
0.46
P/B
0.56
P/C
-
P/FCF
-3.61
Quick Ratio
2.56
Current Ratio
4.68
Debt / Equity
0.32
LT Debt / Equity
0.31
-
-
EPS (TTM)
0.11
EPS next Y
0.49
EPS next Q
-
EPS this Y
-79.46%
EPS next Y
343.22%
EPS next 5Y
343.22%
EPS last 5Y
103.44%
Revenue last 5Y
44.49%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
12.58%
SMA50
-12.02%
SMA100
-31.35%
Inst Own
-
Inst Trans
-
ROA
8%
ROE
13%
ROC
0.17%
Gross Margin
52%
Oper. Margin
20%
Profit Margin
11%
Payout
-
Shs Outstand
10.25M
Shs Float
0
-
-
-
-
Target Price
-
52W Range
6.78-19.85
52W High
-53.42%
52W Low
+47.5%
RSI
43.15
Rel Volume
0.61
Avg Volume
13.51K
Volume
8.28K
Perf Week
-5.85%
Perf Month
27.71%
Perf Quarter
-31.66%
Perf Half Y
-35.68%
-
-
-
-
Beta
-2.11876
-
-
Volatility
0.19%, 0.72%
Prev Close
-0.67%
Price
8.85
Change
-3.07%
ALBIO.PA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 3.42 | 3.75 | 17.27 | 37.07 | 19.21 | |
| Net income per share | -0.01 | 0.12 | 3.52 | 10.08 | 2.07 | |
| Operating cash flow per share | 0 | 0 | 3.55 | 10.65 | 0.48 | |
| Free cash flow per share | 0 | 0 | 2.53 | 8.8 | -2.46 | |
| Cash per share | 0.22 | 0.27 | 3.49 | 12.8 | 8.52 | |
| Book value per share | 3.2 | 3.33 | 6.66 | 16.26 | 15.88 | |
| Tangible book value per share | 0.5 | 0.11 | 3.32 | 11.21 | 8.33 | |
| Share holders equity per share | 3.2 | 3.33 | 6.66 | 16.26 | 15.88 | |
| Interest debt per share | 0.59 | 1.11 | 1.79 | 3.46 | 5.14 | |
| Market cap | 22.84M | 23.75M | 147.94M | 271.57M | 141.22M | |
| Enterprise value | 26.17M | 31.87M | 132.6M | 174.85M | 106.13M | |
| P/E ratio | -421.15 | 21.29 | 4.72 | 2.61 | 6.65 | |
| Price to sales ratio | 0.73 | 0.69 | 0.96 | 0.71 | 0.72 | |
| POCF ratio | 0 | 0 | 4.68 | 2.47 | 28.56 | |
| PFCF ratio | 0 | 0 | 6.57 | 2.99 | -5.62 | |
| P/B Ratio | 0.78 | 0.78 | 2.49 | 1.62 | 0.87 | |
| PTB ratio | 0.78 | 0.78 | 2.49 | 1.62 | 0.87 | |
| EV to sales | 0.84 | 0.93 | 0.86 | 0.46 | 0.54 | |
| Enterprise value over EBITDA | 63.9 | 17.18 | 2.51 | 1.18 | 1.68 | |
| EV to operating cash flow | 0 | 0 | 4.19 | 1.59 | 21.46 | |
| EV to free cash flow | 0 | 0 | 5.89 | 1.93 | -4.22 | |
| Earnings yield | 0 | 0.05 | 0.21 | 0.38 | 0.15 | |
| Free cash flow yield | 0 | 0 | 0.15 | 0.33 | -0.18 | |
| Debt to equity | 0.18 | 0.33 | 0.27 | 0.21 | 0.32 | |
| Debt to assets | 0.13 | 0.21 | 0.14 | 0.13 | 0.2 | |
| Net debt to EBITDA | 8.14 | 4.38 | -0.29 | -0.65 | -0.55 | |
| Current ratio | 3.68 | 3.31 | 2.6 | 3.25 | 4.68 | |
| Interest coverage | -0.34 | 8.05 | 203.88 | 405.67 | 77.57 | |
| Income quality | 0 | 0 | 1.01 | 1.03 | 0.32 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.24 | 0.26 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.63 | 0.62 | 0.27 | 0.19 | 0.31 | |
| Capex to operating cash flow | 0 | 0 | -0.29 | -0.17 | -6.08 | |
| Capex to revenue | 0 | 0 | -0.06 | -0.05 | -0.15 | |
| Capex to depreciation | 0 | 0 | -1.26 | -9.33 | -1.12 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.65 | 3.02 | 22.96 | 60.73 | 27.23 | |
| ROIC | 0 | 0.04 | 0.98 | -5.04 | 0.39 | |
| Return on tangible assets | 0 | 0.06 | 0.39 | 0.48 | 0.12 | |
| Graham Net | -0.56 | -1.17 | -1.2 | 4.5 | 1.23 | |
| Working capital | 9.04M | 10.54M | 43.7M | 137.64M | 125.52M | |
| Tangible asset value | 4.57M | 989.3K | 29.6M | 115.67M | 85.24M | |
| Net current asset value | 2.21M | -1.86M | 19.61M | 97.64M | 66.16M | |
| Invested capital | 0.18 | 0.33 | 0.27 | 0.21 | 0.32 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.88M | 3.4M | 9.21M | 20.32M | 21.01M | |
| Average inventory | 6.37M | 6.95M | 13.36M | 25.11M | 34.41M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 68.08 | 98.85 | 62.28 | 54.3 | 61.23 | |
| Days of inventory on hand | 151.65 | 189.78 | 82.25 | 64.56 | 145.88 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 5.36 | 3.69 | 5.86 | 6.72 | 5.96 | |
| Inventory turnover | 2.41 | 1.92 | 4.44 | 5.65 | 2.5 | |
| ROE | 0 | 0.04 | 0.53 | 0.62 | 0.13 | |
| Capex per share | 0 | 0 | -1.02 | -1.84 | -2.94 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2020-12-31 | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value | -15.34M | -12.07M | -96.72M | -44.07M | -35.09M | |
| P/E ratio | 0 | 0 | 0 | 0 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0 | 0 | 0 | 0 | 0 | |
| PTB ratio | 0 | 0 | 0 | 0 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0 | 0 | 0 | 0 | 0 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.27 | 0.63 | 0.21 | 0.28 | 0.32 | |
| Debt to assets | 0.14 | 0.33 | 0.13 | 0.2 | 0.2 | |
| Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
| Current ratio | 2.6 | 2.05 | 3.25 | 5.63 | 4.68 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.27 | 0.18 | 0.19 | 0.28 | 0.31 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 0 | 0 | 0 | 0 | |
| ROIC | 0 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | 43.7M | 101.64M | 137.64M | 132.48M | 125.52M | |
| Tangible asset value | 29.6M | 88.82M | 115.67M | 106.48M | 85.24M | |
| Net current asset value | 19.61M | 77.13M | 97.64M | 87.48M | 66.16M | |
| Invested capital | 0.27 | 0.63 | 0.21 | 0.28 | 0.32 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0 | 0 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ALBIO.PA Frequently Asked Questions
What is Biosynex SA stock symbol ?
Biosynex SA is a FR stock and trading under the symbol ALBIO.PA
What is Biosynex SA stock quote today ?
Biosynex SA stock price is $8.85 today.
Is Biosynex SA stock public?
Yes, Biosynex SA is a publicly traded company.
Company Profile
- Volume Average 13.51K
- Market Capitalization 90.74M
- Employee 380
- CEO Mr. Larry Abensur
- Headquarters Illkirch-Graffenstaden,FR
- IPO Date 2011-03-21
-
Website
https://www.biosynex.com 
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women's health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.
